Better Health Publishing — Results from an 18 month phase II clinical trial on the benefits of dietary supplement modified citrus pectin in biochemically relapsed prostate cancer will be presented at the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium, Feb 16-18. Results showed that 18 months of treatment with researched modified citrus pectin (P-MCP) reduced prostate cancer progression, stabilized or decreased PSA, and slowed PSA doubling time (PSADT) without hormonal interference or side effects. These results highlight the clinically relevant benefits of P-MCP in prostate cancer Figure 1: Results from 18 month follow-up on P-MCP in BRPC presented...